Importance Current guidelines recommend the use of non–vitamin K antagonist oral
anticoagulants (NOACs) for stroke prevention in patients with atrial fibrillation (AF). Data …

Background and Purpose—Recurrent bleeding associated with oral anticoagulants (OACs)
causes a dilemma in patients with atrial fibrillation (AF) sustaining an intracerebral …

No patient with past history of ICH was enrolled to any of the phase III AF trials (including
AVERROES [Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial …

Background and Purpose—Warfarin is associated with a better net clinical benefit compared
with no treatment in patients with nonvalvular atrial fibrillation (AF) and history of intracranial …

Background To investigate the effectiveness and safety of withholding or restarting
antithrombotic agents, and different antithrombotic therapies among patients with atrial …

Background—The risk of further intracranial hemorrhage (ICH) and the benefit of stroke risk
reduction with the use of oral anticoagulants for patients who have atrial fibrillation with a …

Non–vitamin K antagonist oral anticoagulants (NOACs) are effective at preventing stroke in
patients with atrial fibrillation (AF). However, little is known about the management of …

Importance Vitamin K antagonist (eg, warfarin) use is nowadays challenged by the non–
vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation …

Background Several non–vitamin K antagonist oral anticoagulant (NOAC) alternatives to
warfarin are available for stroke prevention in atrial fibrillation (AF). We aimed to describe …

Background and Purpose—Despite treatment with oral anticoagulants, patients with
nonvalvular atrial fibrillation (AF) may experience ischemic cerebrovascular events. The …